CONTEMPORARY ANTICOAGULANT TREATMENT OF PULMONARY EMBOLISM

  • Greta Musteikienė
  • Skaidrius Miliauskas
DOI: https://doi.org/10.37499/PIA.55
Keywords: heparin, low molecular weight heparins, fondaparinux, warfarin, non-vitamin K antagonist oral anticoagulants

Abstract

Venous thromboembolism, clinically occurring as deep vein thrombosis or pulmonary embolism, is one of the most common acute cardiovascular syndromes. Heparin and its products are the mainstays in treatment of venous thromboembolism, for more than 50 years. In recent years several new anticoagulants were approved. Its mechanisms of action, advantages and adverse reactions are reviewed in this article.

Author Biographies

Greta Musteikienė

Department of Pulmonology, Medical Academy, Lithuanian University of Health Sciences 

Skaidrius Miliauskas

Department of Pulmonology, Medical Academy, Lithuanian University of Health Sciences 

How to Cite
1.
Musteikienė G, Miliauskas S. CONTEMPORARY ANTICOAGULANT TREATMENT OF PULMONARY EMBOLISM [Internet]. PIA 2020 May;4(1):15-20.[cited 2024 Nov. 25 ] Available from: http://pia.pulmoalerg.lt/index.php/PIA/article/view/55
Issue
Vol 4 No 1 (2020): Pulmonology and Allergology
Section
Pulmonology and allergology